On September 25, 2023 we celebrated Heffter’s 30th birthday. You can see the list of the 156 research projects that have received Heffter funding since then here. As of 2020, Heffter-affiliated researchers accounted for 63% (17 of 27) of the top-cited articles on classic psychedelics. We...
Here is our annual report of our progress this past year and future plans. Heffter’s largest supported study was recently completed, “Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder: A Randomized Clinical Trial.”...
August 30, 2022 Dear Dr. Greer, It is my pleasure to thank you for the Heffter Research Institute’s recent gift of $138,405 to support Dr. Yvan Beaussant’s PATH study for patients receiving hospice care. Thanks to your ongoing support, the first PATH study participant has successfully completed...
Johns Hopkins Medicine was awarded a grant from the National Institutes of Health (NIH) to explore the potential impacts of psilocybin on tobacco addiction. This is the first NIH grant awarded in over a half century to directly investigate the therapeutic effects of a classic...
First, there have been changes at Heffter since our last newsletter. Carey Turnbull has succeeded George Greer as President. George has retired as Medical Director and is now Board Chair. Dave Nichols is Vice-President, and all three make up the Heffter Executive Committee....
"JUDY WOODRUFF: Now: why some psychiatrists and researchers are giving psychedelic drugs a second look as a possible way of treating depression and some mental illnesses. The idea had been shunned for years, but now some say a time for larger trials with the drugs is...
2016 has been a watershed year for the Heffter Research Institute and its programs! We believe that our work is contributing to what we hope will be a paradigm shift in the way that many psychiatric and addictive disorders are treated. We hope you enjoy reading about all of the great things we have accomplished this past year.
Johns Hopkins and NYU Studies of Psilocybin for Anxiety and Depression in Cancer Patients
Our big news is the publication of two Heffter-supported studies on psilocybin treatment of anxiety and depression in cancer patients at Johns Hopkins and NYU on December 1. You can access the free full-text articles by clicking on those links.
The story about these studies was widely covered by the media. For example, it was on the front page of the NY Times that day: A Dose of a Hallucinogen From a ‘Magic Mushroom,’ and Then Lasting Peace. An analysis of all the media reporting indicates that the studies were covered in at least 600 media outlets that collectively reach millions of readers and viewers.*
So psilocybin research is now virtually common knowledge. At the end of this letter is the latest list of weblinks to all the online stories we found that mention Heffter’s role in this research.
Heffter Research Institute is proud to have supported new psilocybin studies published December 1 in The Journal of Psychopharmacology reporting the effectiveness of using psilocybin to reduce depression, anxiety and existential distress in cancer patients. Below is a round-up of articles discussing the recent findings...